<DOC>
	<DOCNO>NCT01649284</DOCNO>
	<brief_summary>This open-label , multi-center , single-arm trial , design provide early access afatinib provide additional information safety efficacy afatinib advance NSCLC patient harbor EGFR mutation .</brief_summary>
	<brief_title>Afatinib Expanded Access Program</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : Patients : 1. locally advanced metastatic NonSmall Cell Lung Cancer ( NSCLC ) 2 . Epidermal Growth Factor Receptor ( EGFR ) mutationpositive result per institution 's test methodology . 3. male female patient age &gt; =18 year 4 . Adequate organ function , define follow : 1 . Left Ventricular Ejection Fraction ( LVEF ) &gt; 50 % within institution normal value 2 . Absolute Neutrophil Count ( ANC ) &gt; 1500/mm3 . 3 . Platelet count &gt; 75,000/mm3 4 . Serum creatinine &lt; 1.5 time upper limit normal 5 . Total Bilirubin &lt; 1.5 time upper limit ( institutional ) normal . 6 . Aspartate Amino Transferase ( AST ) Alanine Amino Transferase ( ALT ) &lt; three time upper limit ( institutional ) normal ( ULN ) . 5 . ECOG score 0 2 6. write informed consent patient guardian prior admission trial consistent International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) guideline local law . Exclusion criterion : Patients : 1. hormonal anticancer treatment within 2 week prior start trial treatment ( continue use antiandrogens and/or gonadorelin analogue treatment prostate cancer permit ) 2 . Radiotherapy within 14 day prior drug administration , except follow : 1 . Palliative radiation organ chest may allow 2 week prior drug administration , 2 . Single dose palliative treatment symptomatic metastasis outside allowance discuss sponsor prior enrol . 3. major surgery within 4 week start trial treatment schedule surgery project course trial 4. know hypersensitivity afatinib excipients 5. history presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure New York Heart Association ( NYHA ) classification 3 , unstable angina poorly control arrhythmia determine treat physician . Myocardial infarction within 6 month prior start trial treatment . 6. Women ChildBearing Potential ( WOCBP ) men able father child , unwilling abstinent use adequate contraception prior trial entry , duration trial participation least 2 week treatment end . 7. childbearing potential : ) nursing b ) pregnant c ) use acceptable method birth control , plan continue use method throughout trial and/or agree submit pregnancy test require protocol 8. history concomitant condition , opinion treat physician , would compromise patient 's ability comply trial interfere evaluation safety trial drug 9. previous concomitant malignancy sit , except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 3 year consider cure . 10. require treatment prohibit concomitant medication list Section 4.2.2 protocol stop duration trial participation 11. know preexist interstitial lung disease 12. presence poorly control gastrointestinal disorder could affect absorption trial drug base treat physician assessment . 13. active hepatitis B infection , active Hepatitis C ( HEP C ) infection and/or know Human Immunodeficiency Virus ( HIV ) carrier . 14. meningeal carcinomatosis 15. symptomatic brain metastasis ( patient asymptomatic brain metastasis , previously treat , eligible provide Stable Disease ( SD ) least 4 week stable dos medication )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>